CVS (61) YI (37) PETS (19) RDGT (37) ⌘ Pro Terminal →

Guardian Pharmacy Services Inc. (Class A) (GRDN) — RQD Stock Rating Cockpit

$40.45 +0.30% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $40.57

Guardian Pharmacy Services Inc. (Class A) (GRDN) earns a Roarable Rating of B- (Buy) with 71/100 RQD Confidence. High-quality cash engine (20% profit margin, 38% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 71/100 (B-) historically ranked in the Top 14% of excess returns over the next 90 days (+6.8% avg 90D alpha vs SPY • 68.4% hit rate) →

ROARABLE B- • BUY Cap $2.56B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on GRDN Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is GRDN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Guardian Pharmacy Services Inc. (Class A) (NYSE: GRDN) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $40.45 (+0.30% 1D, market cap $2.56B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 15/20. Across 146 tracked Consumer Staples issuers, GRDN ranks #11 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does GRDN compare to CVS and YI in the Consumer Staples sector?

▼

Within the Consumer Staples sector (Retail-Drug Stores and Proprietary Stores), GRDN carries a Roarable B- (71/100 RQD), trailing P/E of 52.1x, gross margin of 20.2%, and ROIC of 37.7%. By comparison, CVS (CVS Health Corporation) holds a C- grade (61/100 RQD, P/E 65.3x, ROIC 2.6%, cap $115.53B) and YI (111 Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -20.5%, cap $26.2M). Among the 5-stock peer group, GRDN leads on earnings multiple (52.1x) while GRDN leads on capital efficiency (37.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for GRDN?

▼

Per GRDN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001802255), Guardian Pharmacy Services Inc. (Class A) generated $1.45B in revenue (+17.9% YoY), $49.2M in net income, and $100.3M in free cash flow against $412.7M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (20% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Priced at 52x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $40.57 (+0.29%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 17/20 (A-) • 6.9% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 71/100 (B-) historically ranked in the Top 14% of excess returns over the next 90 days (+6.8% avg 90D alpha vs SPY • 68.4% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B-

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+5.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GRDN)Realized 20D OHLCV Swing Band: ±7.3%

Deterministic 5-Pillar Attribution (71/100 Composite)

🔍 WHY GRDN SCORES 71/100 (B-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (25% of score)

Altman Z-Score 12.39 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+17/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 6.9% FCF Margin ($100.3M FCF) & 20.2% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning9/20 pts (-11 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-11 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade A-$40.47-0.8% Next Q

Q2 (-2Q)

Grade B+$40.14-2.4% Next Q

Q3 (-1Q)

Grade B+$39.19+3.2% Next Q

Current

Grade B-$40.45+6.8% Hist 90D α

Trajectory: A- (79) → B- (71)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the GRDN Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 71/100 (B-) score, GRDN faces multiple-compression risk if 52.1x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Priced at 52x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 17.7% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($41.10) or 200D SMA ($38.14) invalidates the momentum regime and cuts Target Base ($42.82) toward Bear Floor ($33.17).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GRDN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “GRDN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 71%NO 29%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

49.330 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

12.39>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE64% OF RANGE

L: $26$40.45H: $48

1. Money & Cash Health● HEALTHY

Are profits real cash in the bank?

Real cash coming in backs up reported profits (20% profit margin and healthy balance-sheet cushion).

Factor Grade: A-RQD 17 / 20

2. Big Money & Insiders● NEUTRAL

Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: C-RQD 24 / 40

3. Hidden Risks & Market Weather● ALL CLEAR

SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: BRQD 30 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bullish on GRDN

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BULLISH (85)

37.7% ROIC with 20.2% gross margin and 3.91% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (90)

Altman-Z 12.39 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (60)

24/40 institutional & smart-money positioning score with 12/20 macro alignment.

Bull Case: Why Buyers Like GRDN

✓Strong cash generator (20% profit margin)—profits are backed by real money, not accounting tricks.
✓Company leadership has skin in the game with net positive insider conviction.
✓Clean SEC annual filing review with no major hidden accounting time-bombs.

Bear Case: What Could Go Wrong

!Priced at 52x earnings—high expectations leave less room for a lukewarm quarter.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (GRDN Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

GRDN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +10.40%🛡️ HOLDING TREND SUPPORT

2026-11-02O $40.33H $40.45L $40.33C $40.45VOL 208.0K

RES: $49.93SUP: $39.15SMA50: $41.10SMA200: $38.14

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GRDN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GRDN Butterfly Map → + Track GRDN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

37.5%/yr Implied 5Y Growth

vs. +17.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on GRDN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GRDN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for GRDN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GRDN)

Consumer Staples Rank #11 of 146 ⚔️ CVS vs GRDN Full Matrix →

1. Head-to-Head Consumer Staples Peer Comparison (GRDN vs. CVS, YI, PETS, RDGT)

Industry: Retail-Drug Stores and Proprietary Stores (5 Tracked Issuers)

Across 146 tracked Consumer Staples securities in the Roarable RQD universe, Guardian Pharmacy Services Inc. (Class A) (GRDN) ranks #11 by composite RQD confidence (71/100, grade B-) and #53 by equity capitalization ($2.56B). Within this direct 5-issuer industry benchmark cohort, GRDN leads on earnings valuation at 52.1x trailing P/E, while GRDN leads on capital efficiency and profitability with 37.7% ROIC and 20.2% gross margin. GRDN currently leads its immediate peer cohort in composite quantitative strength at 71/100 (B-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
GRDN ACTIVE Guardian Pharmacy Services Inc. (Class A)	B-	71/100	52.1x	20.2%	37.7%	+0.30%	$2.56B	Benchmark Subject
CVS CVS Health Corporation	C-	61/100	65.3x	45.0%	2.6%	+0.42%	$115.53B	/cvs-vs-grdn →
YI 111 Inc.	D-	37/100	—	5.8%	-20.5%	+0.34%	$26.2M	/yi-vs-grdn →
PETS PetMed Express Inc.	E	19/100	—	28.1%	-35.0%	-0.84%	$25.6M	/pets-vs-grdn →
RDGT Ridgetech Inc.	D-	37/100	—	3.6%	—	-2.45%	$3.0M	/rdgt-vs-grdn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001802255

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Guardian Pharmacy Services Inc. (Class A) (GRDN) reported GAAP revenue of $1.45B (+17.9% vs. FY2024 revenue of $1.23B ) , GAAP net income of $49.2M, operating cash flow of $100.3M, and free cash flow of $100.3M (+73.0% YoY). On the balance sheet, GRDN closed FY2025 with $412.7M in total assets against $0 in total debt (Altman Z-Score: 12.39, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.45B	$49.2M	$100.3M	$100.3M	$412.7M	—
FY2024 (FY)	2024-12-31	$1.23B	-$110.0M	$58.0M	$58.0M	$320.8M	—

3. GRDN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GRDN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does GRDN compare to CVS and YI in the Consumer Staples sector?

What are the biggest fundamental strengths and SEC risk factors for GRDN?

Where is GRDN trading relative to its 50-day, 200-day, and 52-week technical levels?

GRDN last traded at $40.45 (+0.30% on volume of 208,031 shares), positioning the stock -1.58% below its 50-day simple moving average ($41.10) and +6.06% above its 200-day simple moving average ($38.14). Across its 52-week range of $26.34 to $48.33, GRDN sits at the 64.2% percentile with a 14-day RSI of 49.3 (NEUTRAL RANGE) and an implied next-earnings move of ±7.3% ($37.50 to $43.40).

GRDN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell GRDN stock right now?

Guardian Pharmacy Services Inc. (Class A) (GRDN) currently earns a Roarable Rating of B- (Buy — BUY) with 71/100 RQD Confidence. High-quality cash engine (20% profit margin, 38% return on capital) with steady institutional support.

What is GRDN's 12-month price target and RQD AI Jury consensus?

GRDN's 12-month base price target is $42.82 (range $33.17 to $50.75), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: GRDN RQD Cockpit GRDN 12M Forecast GRDN Earnings & Move GRDN Dividends & DRIP GRDN Insiders & 13F GRDN Whale Options GRDN Profit Sankey GRDN News & Why